Solence lands €1.6M to improve lives of women with PCOS through AI

Solence, a French healthtech startup focused on women’s hormonal health, has raised €1.6 million in seed funding to advance its AI-driven digital therapeutic platform for polycystic ovary syndrome (PCOS)—a condition impacting up to 20% of women worldwide. The round was led by Impact Shakers Ventures, joined by notable angel investors such as Céline Lazorthes (founder of Leetchi, Mangopay, and Resilience), former JP Morgan executive Berthe Latreille, Systemanova VC founder Stephane Mardel, and BPI France.

Founded in 2022 by Clara Stephenson, Solence was born from her personal journey with PCOS, a condition that went undiagnosed for over a decade despite clear symptoms. Similarly to around 85% of women, she received little to no support until fertility issues prompted further investigation.

“PCOS is one of the great blind spots in women’s healthcare. It’s time to change that,” says Clara. “Ultimately, our vision is to leverage data and environmental factors to better address chronic hormonal conditions among women, with a focus on prevention and improving their healthy life expectancy.”

Solence’s solution is a twelve-week digital program grounded in peer-reviewed science, designed to improve PCOS symptoms and support fertility through lifestyle intervention. The app combines medical knowledge with behavior-change techniques, offering interactive lessons that empower women to better understand and manage their condition.

Solence’s app delivers monthly PCOS health scores to help users track progress, pinpoint symptom triggers, and receive tailored recommendations and resources. The platform is backed by leading experts, including Professor Michel Pugeat, who has been treating PCOS since 2003, and Dr. Nour Mimouni, a neuroscience researcher. Both serve on Solence’s scientific advisory board.

“We backed Clara and Solence not only because PCOS is a condition that affects 1 in 7 women and can have serious consequences for women’s health and wellbeing, but also because Clara brings a unique perspective, experience and network to solving this challenge,” said Yonca Breackman, Founding Partner at Impact Shakers Ventures.

The newly secured funding will fuel the next stage of growth, including further product development, expanding the team, establishing clinical collaborations, and scaling distribution. Solence aims to bridge the gap between clinical guidelines— which emphasize lifestyle changes as first-line treatment—and the current overreliance on medication in PCOS care.